广东探索药采新政，创新药ETF(159992)实时净申购超4000万份，迪哲医药-U、迈威生物-U、美迪西领涨。

和讯网07-05

2024年7月5日，创新药板块大幅修复。盘面上，迪哲医药-U领涨，迈威生物-U、美迪西跟涨，创新药ETF市场热度较高，过去5个交易日日均成交额达1.54亿元。中信建投表示，6月20日，广东省药品交易中心发布《广东省药品交易中心关于征询药品拟带量采购意向品种清单的通知》，广东将探索带量采购新机制，向相关企业征询2024年药品拟带量采购意向品种，品种范围包括20个基药以及431个国谈药物。此举标志着...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2449258347?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-07-05 14:26","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2449258347","market":"sh","top_or_hot":-1,"title":"广东探索药采新政，创新药ETF(159992)实时净申购超4000万份，迪哲医药-U、迈威生物-U、美迪西领涨。","media":"和讯网","content":"<div>\n<p>2024年7月5日，创新药板块大幅修复。盘面上，迪哲医药-U领涨，迈威生物-U、美迪西跟涨，创新药ETF市场热度较高，过去5个交易日日均成交额达1.54亿元。中信建投表示，6月20日，广东省药品交易中心发布《广东省药品交易中心关于征询药品拟带量采购意向品种清单的通知》，广东将探索带量采购新机制，向相关企业征询2024年药品拟带量采购意向品种，品种范围包括20个基药以及431个国谈药物。此举标志着...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240705160533957b0dc6&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>广东探索药采新政，创新药ETF(159992)实时净申购超4000万份，迪哲医药-U、迈威生物-U、美迪西领涨。</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n广东探索药采新政，创新药ETF(159992)实时净申购超4000万份，迪哲医药-U、迈威生物-U、美迪西领涨。\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-05 14:26 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240705160533957b0dc6&s=b><strong>和讯网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2024年7月5日，创新药板块大幅修复。盘面上，迪哲医药-U领涨，迈威生物-U、美迪西跟涨，创新药ETF市场热度较高，过去5个交易日日均成交额达1.54亿元。中信建投表示，6月20日，广东省药品交易中心发布《广东省药品交易中心关于征询药品拟带量采购意向品种清单的通知》，广东将探索带量采购新机制，向相关企业征询2024年药品拟带量采购意向品种，品种范围包括20个基药以及431个国谈药物。此举标志着...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240705160533957b0dc6&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688192","symbol_name":"迪哲医药","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240705160533957b0dc6&s=b","article_id":"2449258347","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240705160533957b0dc6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2449258347","pubTimestamp":1720160777,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"2024年7月5日，创新药板块大幅修复。盘面上，迪哲医药-U领涨，迈威生物-U、美迪西跟涨，创新药ETF市场热度较高，过去5个交易日日均成交额达1.54亿元。此举标志着广东省在深化医疗保障制度改革、优化药品供应保障体系方面迈出了新的一步此措施有助于进一步规范药品市场，保障公众用药需求，提高药品可及性、促进创新药行业健康发展。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159992":"创新药","515120":"创新药ETF","688062":"迈威生物","688192":"迪哲医药","688202":"美迪西","BK0239":"医药制造","BK0216":"研究试验"},"translate_title":"Guangdong is exploring the new policy of drug procurement, and the real-time net subscription of innovative drug ETF (159992) exceeded 40 million shares, led by Dizhe Pharmaceutical-U, Maiwei Bio-U, and Medicilon.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"515120":1,"688062":1,"688192":1,"688202":1},"content_text":"2024年7月5日，创新药板块大幅修复。盘面上，迪哲医药-U领涨，迈威生物-U、美迪西跟涨，创新药ETF市场热度较高，过去5个交易日日均成交额达1.54亿元。中信建投表示，6月20日，广东省药品交易中心发布《广东省药品交易中心关于征询药品拟带量采购意向品种清单的通知》，广东将探索带量采购新机制，向相关企业征询2024年药品拟带量采购意向品种，品种范围包括20个基药以及431个国谈药物。此举标志着广东省在深化医疗保障制度改革、优化药品供应保障体系方面迈出了新的一步此措施有助于进一步规范药品市场，保障公众用药需求，提高药品可及性、促进创新药行业健康发展。本次带量采购工作的核心是在现行医保支付标准下，通过采购的形式来加快国谈品种的进院和放量，创新药企盈利预期向好。相关产品： 创新药ETF以上内容与数据，与界面有连云频道立场无关，不构成投资建议。据此操作，风险自担。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2449258347"}